TG Therapeutics ((TGTX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The clinical study titled ‘Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)’ aims to assess the pharmacokinetics and pharmacodynamics of ublituximab in children aged 10 to under 18 with relapsing multiple sclerosis. The study also seeks to compare the efficacy of ublituximab with fingolimod, a current treatment option, and evaluate its long-term safety and efficacy.
The study tests ublituximab, an intravenous drug, against fingolimod, an oral capsule, and placebo. Ublituximab is intended to treat relapsing multiple sclerosis by targeting specific immune cells.
This interventional study is designed with a randomized, parallel assignment model and quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary goal is treatment-focused.
The study is set to begin on October 22, 2025, with key dates for primary completion and estimated completion yet to be announced. The latest update was submitted on the same start date, indicating preparations are underway.
For TG Therapeutics, this study could significantly impact its stock performance, especially if ublituximab proves superior to existing treatments like fingolimod. Investors will be keenly watching for updates, as positive results could enhance the company’s market position against competitors in the multiple sclerosis treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.